LIDOCAINE HYDROCHLORIDE INJECTION SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

LIDOCAINE HYDROCHLORIDE

제공처:

LABORATOIRE AGUETTANT

ATC 코드:

N01BB02

INN (국제 이름):

LIDOCAINE

복용량:

20MG

약제 형태:

SOLUTION

구성:

LIDOCAINE HYDROCHLORIDE 20MG

관리 경로:

BLOCK/INFILTRATION

패키지 단위:

15G/50G

처방전 유형:

Ethical

치료 영역:

LOCAL ANESTHETICS

제품 요약:

Active ingredient group (AIG) number: 0101280001; AHFS:

승인 상태:

APPROVED

승인 날짜:

2020-06-17

제품 특성 요약

_Lidocaine Hydrochloride Injection _
_Page 1 of 23_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Lidocaine Hydrochloride Injection
Sterile Solution, 100 mg / 5 mL (20 mg / mL), Intravenous
House Standard
Antiarrhythmic
C01BB01
Preservative-Free. Single use.
Laboratoire Aguettant
1 rue Alexander Fleming
69007 Lyon
France
Imported and Distributed by:
Aguettant Canada Inc.
1470 Peel Suite A-152
Montreal, QC, H3A 1T1
Submission Control No: 234178
Date of Initial Approval:
November 04, 2021
_Lidocaine Hydrochloride Injection _
_Page 2 of 23_
RECENT MAJOR LABEL CHANGES
Not applicable.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES.............................................................................
2
TABLE OF CONTENTS
...................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
1
INDICATIONS.......................................................................................................
3
1.1
Pediatrics...............................................................................................................
3
1.2
Geriatrics
...............................................................................................................
3
2
CONTRAINDICATIONS.......................................................................................
3
3
DOSAGE AND ADMINISTRATION
.................................................................... 3
3.1
Dosing Considerations
.........................................................................................
3
3.2
Recommended Dose and Dosage Adjustment
................................................... 4
3.3
Administration
.......................................................................................................
4
4
OVERDOSAGE
...............................................................................